Metsera (NASDAQ:MTSR) Shares Up 5.6% – Here’s What Happened

Metsera, Inc. (NASDAQ:MTSR) was up 5.6% on Thursday . The company traded as high as $29.69 and last traded at $29.69. Approximately 86,736 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 662,272 shares. The stock had previously closed at $28.11.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Bank of America started coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock. Evercore ISI assumed coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company. Cantor Fitzgerald began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock. Finally, Guggenheim assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target on the stock.

Metsera Price Performance

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.